Company Description
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients.
The company’s Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.
It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.
The company’s pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28.
It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program.
The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2005 |
| IPO Date | Feb 4, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | John Celebi |
Contact Details
Address: 1405 Research Boulevard, Suite 125 Rockville, Maryland 20850 United States | |
| Phone | 240 243 8000 |
| Website | senseibio.com |
Stock Details
| Ticker Symbol | SNSE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001829802 |
| CUSIP Number | 81728A108 |
| ISIN Number | US81728A1088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John K. Celebi M.B.A. | President, Chief Executive Officer and Director |
| Dr. Edward Van der Horst Ph.D. | Chief Scientific Officer |
| Josiah Craver | Senior Vice President of Finance, Principal Financial Officer and Principal Accounting Officer |
| Lora Pike | Vice President of Investor Relations and Communications |
| Christopher W. Gerry J.D. | Senior Vice President, General Counsel and Secretary |
| Stephanie Krebs M.B.A., M.S. | Chief Business Officer |
| Dr. Aaron Weitzman FACP, M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2024 | 8-K | Current Report |
| Sep 20, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Jul 12, 2024 | 8-K | Current Report |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 13, 2024 | 8-K | Current Report |
| Jun 3, 2024 | 8-K | Current Report |
| May 23, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |